Case Clinical Trials Unit

描述（由申请人提供）：病例临床试验单位（CTU）包括四个高产的临床研究中心：克利夫兰的病例/UHC和Metro Health医疗中心、辛辛那提和坎帕拉的联合临床研究中心。这四个CRS研究中心都是表现最好的ACTG治疗试验中心，具有出色的应计利润、出色的绩效评估和在网络领导中的重要作用，这是科学生产力。这个CTU的一个关键主题是我们的临床研究组合与我们的基础和转化研究计划的密切联系。因此，Case CTU的四个CRS站点为企业带来了全面的研究计划。由教师谁是在各自领域的国家和国际领导人的带领下，这些单位准备作出实质性贡献，由ACTG目标的每个优先领域：炎症/终末器官疾病，治愈，肝炎和结核病。Case/UHC CRS自网络成立以来一直是MTN的富有成效的成员，并建议在MTN中开展对过去10年来一直在开发的高效杀微生物剂候选物（5 P12-RANTES）的研究。病例/UHC和JCRC研究中心均为纳入HVTN提供了强有力的依据。Case/UHC一直在与HVTN 505网络合作，并开发了一个模型外展计划，该计划的入组人数增加了一倍多。辛辛那提大学CRS是一个高效，管理良好的CRS，自1987年以来一直在为ACTG进行临床和转化研究。JCRC是非洲第一个艾滋病毒疫苗试验的地点，可以随时接触到艾滋病毒感染高危人群中的大量受试者，并拥有先进的基础设施，可以成为这一网络的有力贡献者。因此，组成该CTU的四个CRS站点能够为NIAID网络的治疗和预防议程提供持续的领导和贡献。 相关性：NIAID临床试验网络的主要目标包括优化艾滋病毒、结核病和肝炎的治疗，以及旨在防止艾滋病毒感染在美国和发展中国家传播的检测策略。我们的CTU由美国和乌干达的4个顶级临床研究中心组成，由这些领域的国家和国际领导者领导，通过对ACTG，MTN和HVTN的研究议程的贡献，为该企业做出高水平的贡献。

DESCRIPTION (provided by applicant): The Case Clinical Trials Unit (CTU) comprises four highly productive clinical research sites: Case/UHC and Metro Health Medical Center in Cleveland, the University of Cincinnati and the Joint Clinical Research Center in Kampala. Each of these four CRS sites is a top performing ACTG treatment trial site with excellent accruals, outstanding performance evaluations and major roles in the leadership of the network and it is scientific productivity. A key theme of this CTU is the close link of our clinical research portfolo with our basic and translational research programs. Thus the four CRS sites of the Case CTU bring a comprehensive research plan to the enterprise. Led by faculty who are national and international leaders in their fields, these units are poised to make substantive contributions to each of the priority areas targeted by the ACTG: Inflammation/End Organ Disease, Cure, Hepatitis and Tuberculosis. The Case/UHC CRS has also been a productive member of the MTN since the network began and proposes to develop studies in the MTN of a highly effective microbicide candidate (5P12-RANTES) that it has been developing for the past 10 years. Both Case/UHC and JCRC sites provide strong rationale for inclusion in the HVTN. Case/UHC has been working with the network on HVTN 505 and has developed a model outreach program more than doubling its enrollment to this high priority HVTN trial. The University of Cincinnati CRS is a highly efficient, well-managed CRS that has been conducting clinical and translational research for the ACTG since 1987. JCRC, the site of the first HIV vaccine trial in Africa, has ready access to large numbers of subjects in well-defined populations at high risk for HIV infection and has the advanced infrastructure to become a powerful contributor to this network. Thus the four CRS sites that comprise this CTU are positioned to provide sustained leadership and contribution to the treatment and prevention agenda of the NIAID Networks. RELEVANCE: Key objectives of the NIAID Clinical Trials Networks include optimizing the treatment of HIV, tuberculosis and hepatitis, and testing strategies designed to prevent the spread of HIV infection in the US and the developing world. Our CTU that comprises 4 top performing clinical research sites in the US and in Uganda and is led by faculty who are national and international leaders in these fields is poised to sustain high level contributions to this enterprise through contributions to the research agendas of the ACTG, the MTN and the HVTN.